Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)15.61bn
- Net income in JPY7.11bn
- Incorporated2006
- Employees128.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Mergers & acquisitions
| Acquired company | 4587:TYO since announced | Transaction value |
|---|---|---|
| FTP | -29.95% | 277.30m |
Data delayed at least 20 minutes, as of Nov 26 2021 06:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KAKEN PHARMACEUTICAL CO., LTD. | 75.78bn | 12.90bn | 192.49bn | 1.22k | 12.42 | 1.15 | 12.57 | 2.54 | 337.29 | 337.29 | 1,981.20 | 3,657.71 | 0.464 | 2.12 | 3.72 | 62,368,720.00 | 7.90 | 12.22 | 9.10 | 14.84 | 54.13 | 56.33 | 17.02 | 19.99 | 4.59 | -- | 0.0271 | 32.46 | -15.97 | -7.33 | -30.80 | -8.71 | -6.60 | 1.98 |
| Sawai Group Holdings Co Ltd | 194.35bn | 10.96bn | 195.75bn | 3.00k | 17.88 | 0.8662 | 7.25 | 1.01 | 249.99 | 249.99 | 4,434.91 | 5,160.44 | 0.4935 | 1.51 | 3.11 | 64,718,620.00 | 2.34 | 5.02 | 3.25 | 6.78 | 37.18 | 40.03 | 4.75 | 9.65 | 1.44 | 46.63 | 0.2204 | 32.93 | 2.56 | 8.68 | -35.99 | -6.38 | 3.51 | 1.61 |
| Tsumura & Co | 130.31bn | 17.21bn | 269.04bn | 3.83k | 15.58 | 1.17 | 10.45 | 2.06 | 225.00 | 225.00 | 1,703.17 | 2,992.87 | 0.4045 | 0.7505 | 2.65 | 34,022,190.00 | 5.20 | 5.13 | 6.38 | 6.19 | 53.90 | 58.02 | 12.85 | 11.69 | 3.00 | -- | 0.1766 | 33.60 | 6.19 | 3.05 | 11.38 | 4.07 | 4.01 | 0.00 |
| TAKARA BIO INC. | 60.24bn | 17.28bn | 328.37bn | 1.54k | 19.00 | 3.88 | 15.57 | 5.45 | 143.52 | 143.52 | 500.30 | 702.51 | 0.6616 | 1.71 | 5.48 | 39,144,900.00 | 19.05 | 5.77 | 22.23 | 6.37 | 72.27 | 61.33 | 28.79 | 11.66 | 2.67 | -- | 0.00 | 22.95 | 33.33 | 9.16 | 149.99 | 48.23 | 30.09 | 54.80 |
| JCR Pharmaceuticals Co Ltd | 47.52bn | 14.90bn | 335.50bn | 732.00 | 21.56 | 6.84 | 19.92 | 7.06 | 119.98 | 119.98 | 382.67 | 378.32 | 0.6495 | 0.6899 | 3.32 | 64,913,940.00 | 20.36 | 8.29 | 33.25 | 10.68 | 81.51 | 69.85 | 31.35 | 15.61 | 1.22 | -- | 0.278 | 26.88 | 21.40 | 11.52 | 157.36 | 30.96 | 39.71 | 18.13 |
| Hisamitsu Pharmaceutical Co Inc | 120.14bn | 10.56bn | 335.98bn | 2.77k | 30.56 | 1.25 | 22.57 | 2.80 | 129.10 | 129.10 | 1,468.84 | 3,167.71 | 0.3948 | 2.64 | 3.67 | 43,370,040.00 | 3.54 | 5.94 | 3.97 | 6.77 | 59.31 | 62.17 | 8.96 | 12.63 | 5.94 | -- | 0.0052 | 39.53 | -18.78 | -6.69 | -50.52 | -12.25 | -8.03 | 0.8601 |
| Peptidream Inc | 15.61bn | 7.11bn | 369.10bn | 128.00 | 51.83 | 14.89 | 47.83 | 23.65 | 54.77 | 54.77 | 120.22 | 190.73 | 0.6652 | 3.91 | 16.08 | 121,933,600.00 | 30.31 | -- | 33.35 | -- | 83.95 | -- | 45.56 | -- | 5.11 | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Alfresa Holdings Corporation | 2.60tn | 20.39bn | 376.03bn | 12.05k | 16.61 | 0.6887 | 11.51 | 0.1448 | 96.34 | 96.34 | 12,268.25 | 2,323.20 | 1.95 | 16.26 | 4.34 | 215,587,300.00 | 1.53 | 2.64 | 3.85 | 7.25 | 6.84 | 7.33 | 0.7851 | 1.32 | 1.07 | -- | 0.0003 | 27.87 | -3.53 | 0.2069 | -39.16 | -6.87 | 5.04 | 9.94 |
| ROHTO PHARMACEUTICAL CO., LTD. | 189.30bn | 21.32bn | 397.96bn | 6.60k | 18.08 | 2.31 | 14.02 | 2.10 | 186.37 | 186.37 | 1,654.74 | 1,459.50 | 0.795 | 2.37 | 4.18 | 28,699,510.00 | 8.98 | 6.13 | 12.61 | 8.75 | 58.35 | 59.47 | 11.30 | 6.96 | 1.64 | -- | 0.0791 | 22.70 | -3.74 | 1.65 | 8.65 | 12.97 | 16.85 | 6.96 |
| Medipal Holdings Corp | 3.27tn | 30.52bn | 496.63bn | 12.97k | 14.90 | 0.7933 | 9.05 | 0.1521 | 136.35 | 136.35 | 14,639.42 | 2,560.32 | 1.93 | 19.67 | 4.65 | 251,788,700.00 | 2.40 | 2.63 | 6.51 | 7.42 | 6.62 | 7.13 | 1.24 | 1.33 | 1.06 | -- | 0.044 | 25.33 | -1.29 | 1.18 | -36.98 | -4.91 | -16.41 | 8.45 |
Data as of Nov 26 2021. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
22.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| J.O. Hambro Capital Management Ltd.as of 30 Jul 2021 | 7.18m | 5.52% |
| BlackRock Fund Advisorsas of 15 Dec 2020 | 3.78m | 2.91% |
| Nomura Asset Management Co., Ltd.as of 29 Oct 2021 | 3.54m | 2.72% |
| Invesco Advisers, Inc.as of 30 Sep 2021 | 3.05m | 2.35% |
| The Vanguard Group, Inc.as of 05 Nov 2021 | 2.30m | 1.77% |
| Baillie Gifford & Co.as of 18 Nov 2021 | 2.28m | 1.75% |
| Shiozumi Asset Management Co. Ltd.as of 30 Sep 2021 | 2.10m | 1.62% |
| Daiwa Asset Management Co. Ltd.as of 29 Oct 2021 | 1.82m | 1.40% |
| Comgest SAas of 30 Jun 2021 | 1.74m | 1.34% |
| Nikko Asset Management Co., Ltd.as of 05 Nov 2021 | 1.72m | 1.32% |
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
